

# Mozambique **Support for Rotavirus Vaccine**

## This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Mozambique							
2.	Grant number: 1518-MOZ-13b-X; 19-MOZ-13b-X; 15-MOZ-08b-Y							
3.	Date of Decision Letter: 21 December 2017							
4.	Date of the Partnership Framework Agreement: 06 December 2013							
5.	Programme title: New Vaccine Support (NVS), Rotavirus Routine							
6.	Vaccine type: Rotavirus							
7.	Requested product presentation and formulation of vaccine: Rotavirus, 2							
/.	dose(s) schedule							
8.	Programme duration <sup>1</sup> : 2015 -2019							
9.	<ol> <li>Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)</li> </ol>							
		2015-2017	2018	2019	Total <sup>2</sup>			
	amme et (US\$)	US\$11,654,652 <sup>3</sup>	US\$4,303,500	US\$4,371,000	US\$20,329,152			
<ul> <li>10. Vaccine introduction grant (in US\$): Vaccine introduction grant of US\$885,500 disbursed on 10 April 2015. Unspent funds of US\$60,442 reallocated to HSS in November 2017.</li> <li>11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework)</li> </ul>								
Agreement <sup>4</sup>								
Type of supplies to be purchased with Gavi funds in each year			2015-201	7	2018			
Number of Rotavirus vaccines doses					2,070,000			
Annual Amounts (US\$)			US\$11,654,652	25	US\$4,303,500			
12. Procurement agency: UNICEF. The Country shall release its co-financing								
payments each year to UNICEF.								
13. Self-procurement: Not applicable.								

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

> 2 Chemin des Mines 1202 Geneva. Switzerland

Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50

www.gavi.org info@gavi.org

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the Programme.

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>&</sup>lt;sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.



**14. Co-financing obligations:** Reference code: 1518-MOZ-13b-X-C, 19-MOZ-13b-X According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

•	,	
Type of supplies to be	2018	2019
purchased with Country funds in		
each year		
Number of vaccine doses	222,000	225,000
Value of vaccine doses (US\$)	US\$443,866	
Total co-financing payments	US\$458,500	US\$466,000
(US\$) (including freight)		

#### 15. Operational support for campaigns: Not applicable

### 16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

### 17. Financial clarifications: Not applicable

### 18. Other conditions:

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard

Signed by,

On behalf of Gavi

Third F. Thath

Hind Khatib-Othman Managing Director, Country Programmes 21 December 2017